Bioderm Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-05-2024
- Paid Up Capital ₹ 0.70 M
as on 27-05-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2018)
- Profit -8.02%
(FY 2018)
- Ebitda 8.63%
(FY 2018)
- Net Worth -1.55%
(FY 2018)
- Total Assets -21.65%
(FY 2018)
About Bioderm Therapeutics
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M, as per Ministry of Corporate Affairs (MCA) records.
Anjani Trivedi and Tanvi Mehta serve as directors at the Company.
- CIN/LLPIN
U24100MH2010PTC203876
- Company No.
203876
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2010
- Date of AGM
18 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bioderm Therapeutics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anjani Trivedi  | Director | 08-Jun-2010 | Current |
| Tanvi Mehta | Director | 16-Feb-2021 | Current |
Financial Performance and Corporate Structure Insights of Bioderm Therapeutics.
Bioderm Therapeutics Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 8.02% decrease in profit. The company's net worth dipped by a decrease of 1.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioderm Therapeutics?
In 2018, Bioderm Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trivedi Enterprises Private LimitedActive 39 years 2 monthsAnjani Trivedi and Tanvi Mehta are mutual person
Technithon Technologies Private LimitedActive 34 years 11 monthsAnjani Trivedi and Tanvi Mehta are mutual person
Indian Home & Personal Care Industry AssociationActive 13 years 7 monthsTanvi Mehta is a mutual person
Bio-Therapeutic Computers Private LimitedActive 25 years 11 monthsAnjani Trivedi and Tanvi Mehta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioderm Therapeutics?
Unlock and access historical data on people associated with Bioderm Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioderm Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioderm Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
